Literature DB >> 25016954

Assay development for the discovery of semaphorin 3B inducing agents from natural product sources.

Yeonjoong Yong1, Li Pan2, Yulin Ren2, Nighat Fatima3, Safia Ahmed4, Leng Chee Chang5, Xiaoli Zhang6, A Douglas Kinghorn2, Steven M Swanson7, Esperanza J Carcache de Blanco8.   

Abstract

Semaphorins are a class of membrane-bound and secreted proteins. They have been found to regulate basic cell functions such as axonal growth cone guidance and recent studies have focused on their effect on tumor progression. Semaphorin 3B (Sema3B) particularly is a secreted protein that has been known to modulate proliferation and apoptosis, processes that are critical for tumor progression and development. In spite of its importance, there is yet no high-throughput screening assay available to detect or quantify the expression of Sema3B for natural product anticancer drug discovery purposes. Therefore, the development of a new high-throughput bioassay for the discovery of Sema3B inducing agents from natural product sources is described herein. A wide variety of pure compounds and extracts from plants and microorganisms has been found suitable for screening using this Sema3B assay to detect and quantify the effect of Sema3B inducing agents and thereby identify new selective bioactive Sema3B lead compounds for anticancer drug discovery and development. Also, this new bioassay procedure is based on a high-throughput platform using an enzyme-linked immunosorbent assay that involves the optimization of sensitivity and selectivity levels as well as accuracy, reproducibility, robustness, and cost effectiveness.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticancer; ELISA; Natural products; Semaphorin

Mesh:

Substances:

Year:  2014        PMID: 25016954      PMCID: PMC4196688          DOI: 10.1016/j.fitote.2014.07.004

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  36 in total

1.  Unified nomenclature for the semaphorins/collapsins. Semaphorin Nomenclature Committee.

Authors: 
Journal:  Cell       Date:  1999-05-28       Impact factor: 41.582

2.  Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2.

Authors:  Toshihiko Toyofuku; Hong Zhang; Atsushi Kumanogoh; Noriko Takegahara; Fumikazu Suto; Junko Kamei; Kazuhiro Aoki; Masanori Yabuki; Masatsugu Hori; Hajime Fujisawa; Hitoshi Kikutani
Journal:  Genes Dev       Date:  2004-02-20       Impact factor: 11.361

Review 3.  Semaphorins in angiogenesis and tumor progression.

Authors:  Gera Neufeld; Adi D Sabag; Noa Rabinovicz; Ofra Kessler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Isolation, structure elucidation, and biological evaluation of 16,23-epoxycucurbitacin constituents from Eleaocarpus chinensis.

Authors:  Li Pan; Yeonjoong Yong; Ye Deng; Daniel D Lantvit; Tran Ngoc Ninh; Heebyung Chai; Esperanza J Carcache de Blanco; Djaja D Soejarto; Steven M Swanson; A Douglas Kinghorn
Journal:  J Nat Prod       Date:  2012-01-12       Impact factor: 4.050

5.  A dominant negative receptor for specific secreted semaphorins is generated by deleting an extracellular domain from neuropilin-1.

Authors:  M J Renzi; L Feiner; A M Koppel; J A Raper
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

6.  Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.

Authors:  Diane R Bielenberg; Yasuhiro Hida; Akio Shimizu; Arja Kaipainen; Michael Kreuter; Caroline Choi Kim; Michael Klagsbrun
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

7.  Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins.

Authors:  H Chen; Z He; A Bagri; M Tessier-Lavigne
Journal:  Neuron       Date:  1998-12       Impact factor: 17.173

8.  RHOA, SEMA3B, and CKAP2 expression in leukaemia of different types: the results of a pilot experiment.

Authors:  E A Klimov; N L Selivanova; G I Razumnova; O I Rudko; P K Golovatenko-Abramov
Journal:  Folia Biol (Praha)       Date:  2013       Impact factor: 0.906

9.  Receptor complexes for each of the Class 3 Semaphorins.

Authors:  Anil Sharma; Joost Verhaagen; Alan R Harvey
Journal:  Front Cell Neurosci       Date:  2012-07-05       Impact factor: 5.505

10.  The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment.

Authors:  Charlotte Rolny; Lorena Capparuccia; Andrea Casazza; Massimiliano Mazzone; Antonella Vallario; Alessandro Cignetti; Enzo Medico; Peter Carmeliet; Paolo M Comoglio; Luca Tamagnone
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

View more
  1 in total

Review 1.  Discovery of Anticancer Agents of Diverse Natural Origin.

Authors:  A Douglas Kinghorn; Esperanza J Carcache DE Blanco; David M Lucas; H Liva Rakotondraibe; Jimmy Orjala; D Doel Soejarto; Nicholas H Oberlies; Cedric J Pearce; Mansukh C Wani; Brent R Stockwell; Joanna E Burdette; Steven M Swanson; James R Fuchs; Mitchell A Phelps; Lihui Xu; Xiaoli Zhang; Young Yongchun Shen
Journal:  Anticancer Res       Date:  2016-11       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.